1,243 Shares in Johnson & Johnson $JNJ Acquired by Traub Capital Management LLC

Traub Capital Management LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,243 shares of the company’s stock, valued at approximately $190,000.

Several other hedge funds have also recently modified their holdings of JNJ. GFG Capital LLC bought a new stake in Johnson & Johnson in the 2nd quarter worth about $35,000. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter worth approximately $48,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $52,000. Finally, Pandora Wealth Inc. bought a new position in Johnson & Johnson during the first quarter valued at approximately $65,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.5%

Shares of NYSE:JNJ opened at $203.04 on Thursday. The stock has a 50 day moving average of $187.24 and a 200 day moving average of $170.99. The company has a market cap of $489.18 billion, a PE ratio of 19.60, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $203.48. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on JNJ shares. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. HSBC increased their target price on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Finally, Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.